Edition:
India

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

1.40USD
11:02pm IST
Change (% chg)

$-0.02 (-1.41%)
Prev Close
$1.42
Open
$1.42
Day's High
$1.43
Day's Low
$1.39
Volume
32,971
Avg. Vol
153,857
52-wk High
$3.31
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Lincoln Park Capital Fund Reports 8.92% Passive Stake In Cellectar Biosciences, Inc As Of July 11
Tuesday, 14 Jul 2020 

July 13 (Reuters) - Lincoln Park Capital Fund::LINCOLN PARK CAPITAL FUND, LLC REPORTS 8.92% PASSIVE STAKE IN CELLECTAR BIOSCIENCES, INC AS OF JULY 11, 2020 - SEC FILING.  Full Article

Cellectar Biosciences Announces Second Quarter 2019 Loss Per Share $0.46
Monday, 12 Aug 2019 

Aug 12 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q2 LOSS PER SHARE $0.46.AS OF JUNE 30, 2019, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $16.8 MILLION.CONTINUES TO EXPECT TO REPORT TOP-LINE DATA FROM PHASE 2 CLOVER-1 STUDY IN 2019..  Full Article

Cellectar Receives FDA Fast Track Designation For Experimental Lymphoma Drug
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR RECEIVES FDA FAST TRACK DESIGNATION FOR CLR 131 IN DIFFUSE LARGE B-CELL LYMPHOMA.  Full Article

Cellectar Receives FDA Fast Track Status For CLR 131 In Relapsed Or Refractory Multiple Myeloma
Monday, 13 May 2019 

May 13 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR RECEIVES FDA FAST TRACK DESIGNATION FOR CLR 131 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA.  Full Article

Cellectar Biosciences Says Appointed Charles Bernhardt As Interim Chief Financial Officer
Saturday, 9 Mar 2019 

March 8 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES INC - ON MARCH 6, APPOINTED CHARLES T. BERNHARDT AS INTERIM CHIEF FINANCIAL OFFICER OF CO, EFFECTIVE MARCH 9 - SEC FILING.  Full Article

Electrocore Inc. - Announced Appointment Of Brian Posner As Chief Financial Officer
Saturday, 9 Mar 2019 

March 8 (Reuters) - electroCore, Inc. ::ELECTROCORE, INC. - ANNOUNCED APPOINTMENT OF BRIAN POSNER AS CHIEF FINANCIAL OFFICER.ELECTROCORE, INC. - GLENN VRANIAK, CO'S CURRENT CHIEF FINANCIAL OFFICER, WILL BE LEAVING COMPANY TO PURSUE OTHER OPPORTUNITIES.ELECTROCORE, INC. - POSNER JOINS ELECTROCORE FROM CELLECTAR BIOSCIENCES.  Full Article

Cellectar Biosciences Says Brian Posner Gave Notice To Of His Resignation As CFO
Saturday, 16 Feb 2019 

Feb 15 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES INC - BRIAN POSNER GAVE NOTICE TO CELLECTAR BIOSCIENCES OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER.CELLECTAR BIOSCIENCES INC - HAS INITIATED A SEARCH TO IDENTIFY AND RECRUIT A NEW CANDIDATE FOR ROLE OF CHIEF FINANCIAL OFFICER..  Full Article

Cellectar Announces FDA Grants Exemption To Import Alert For CLR 131 Hematology Studies
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES FDA GRANTS EXEMPTION TO IMPORT ALERT FOR CLR 131 HEMATOLOGY STUDIES.CELLECTAR BIOSCIENCES INC - EXEMPTION FOR CLR 131 IS EFFECTIVE IMMEDIATELY FOR ALL HEMATOLOGY STUDIES.CELLECTAR BIOSCIENCES - AWAITS AUTHORIZATION FROM FDA FOR ANY FUTURE SHIPMENTS IN CONNECTION WITH ITS PHASE 1 STUDY OF PEDIATRIC PATIENTS.  Full Article

Cellectar Biosciences Provides Update On FDA Import Alert
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES PROVIDES AN UPDATE ON THE FDA IMPORT ALERT.CELLECTAR BIOSCIENCES INC - SINCE NOTIFICATION OF IMPORT ALERT, CO HAS BEEN ASSISTING CPDC TO SECURE TIMELY REMOVAL OF IMPORT ALERT.CELLECTAR BIOSCIENCES - FDA INITIATED DIRECT TALKS WITH CO FOR POSSIBLE EXEMPTION FOR CLR 131 FROM IMPORT ALERT PLACED ON CPDC.  Full Article

BRIEF-Cellectar To Be Granted EU Patent For Phospholipid Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR TO BE GRANTED EU PATENT FOR PHOSPHOLIPID ETHER (PLE) ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: